GLP-1 Drugs Do Not Increase Pancreatitis Risk in High-Risk Diabetes Patients | Research

The takeaway

Large retrospective analysis of 4.5+ million members finds GLP-1 analogues do not increase recurrent pancreatitis risk in diabetic patients with prior pancreatitis or elevated lipase.

4.5M+ member safety data
No increased pancreatitis recurrence risk with GLP-1 drugs even in high-risk patients

What the researchers found

GLP-1 analogues were not associated with increased recurrent pancreatitis risk in diabetic patients with prior pancreatitis or elevated lipase, in a cohort of >4.5 million members.

Why it matters

Pancreatitis concerns have limited GLP-1 prescribing. Showing safety even in the highest-risk patients removes a major barrier to appropriate use.

How the study worked

Retrospective cohort analysis from a large health maintenance organization (>4.5 million members) comparing pancreatitis recurrence in GLP-1 users vs non-users among high-risk patients.

What this study cannot tell us

Retrospective observational design. Despite large database, the subgroup with prior pancreatitis may still be relatively small. Could not capture unreported mild pancreatitis episodes.

How to read the evidence

Large retrospective cohort — strong real-world safety evidence from a massive population.

When this study was published

Published in 2026; addresses a long-debated GLP-1 safety concern.

The bigger picture

This joins accumulating evidence that the initial pancreatitis safety signal with GLP-1 drugs was likely spurious, supporting their broader clinical use.

Questions still open

Can GLP-1 drugs now be prescribed without pancreatitis disclaimers?
Should current prescribing guidelines be updated to remove pancreatitis warnings?

Common questions

Do GLP-1 drugs cause pancreatitis?

This large study of over 4.5 million people — including high-risk patients with prior pancreatitis — found no increased pancreatitis risk with GLP-1 drugs. Early concerns appear to have been unfounded.

Can I take GLP-1 drugs if I had pancreatitis before?

This study suggests GLP-1 drugs do not increase recurrent pancreatitis risk even in patients with prior episodes. However, discuss your specific history with your doctor.

Read the original research

Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.

Diabetes/metabolism research and reviews, 42(1), e70116

View on PubMed ↗Publisher’s paper ↗

Citation

Calvarysky, Bronya; Gal, Yaara; Kushnir, Shiri; Turjeman, Adi; Shochat, Tzippy; Dotan, Idit; Diker Cohen, Talia. (2026). Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.. Diabetes/metabolism research and reviews, 42(1), e70116. https://doi.org/10.1002/dmrr.70116